Programmed cell death mechanisms are important for the regulation of tumor development
and progression. Evasion of and resistance to apoptosis are significant factors in …

Background: Durable single-agent responses with the IAP antagonist, tolinapant (ASTX660),
have been reported in peripheral T-cell lymphoma (PTCL) and cutaneous TCL (CTCL) …

Introduction: Tolinapant is a potent, non-peptidomimetic antagonist of cIAP1, cIAP2 and
XIAP. In ongoing Phase 2 trial (NCT02503423), tolinapant has shown activity against highly …

Tolinapant (ASTX660) is a potent, nonpeptidomimetic antagonist of cellular inhibitor of
apoptosis proteins 1 and 2 (cIAP1/2) and X-linked IAP, which is currently being evaluated in …

Background: Peripheral T cell lymphomas (PTCL) are a highly aggressive and
heterogeneous group of non-Hodgkin lymphomas that carry a poor prognosis. Treatment …

Immunogenic cell death (ICD) activates both innate and adaptive arms of the immune
system during apoptotic cancer cell death. With respect to cancer immunotherapy, the …

Background: Inhibitors of apoptosis proteins (IAPs) are overexpressed in ALL leading to
resistance to apoptosis and chemo-resistance. Tolinapant, a non-peptidomimetic antagonist …

The traditional view holds that apoptosis is non-immunogenic and does not induce an
inflammatory response. However, recent studies have suggested that certain …

Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent
study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell …

Emerging evidence suggests that the clinical success of conventional chemotherapy is not
solely attributed to tumor cell toxicity, but also results from the restoration of …